ArticleCancer research2019
Genome-Wide RNAi Screen Identifies PMPCB as a Therapeutic Vulnerability in EpCAM
Open access · hybridAbstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Platelet-derived microparticles induce CD8Experimental & molecular medicine · 2026Article
- Pmpcb modulates zebrafish neurogenesis and stress resistance via regulating mitochondria metabolism and function.Molecular neurobiology · 2026Article
- Clinical and genetic analysis of multiple mitochondrial dysfunctions syndrome type 6 caused by biallelicFrontiers in pediatrics · 2026Article
- Regulatory effect of Wnt signaling on mitochondria in cancer: from mechanism to therapy.Apoptosis : an international journal on programmed cell death · 2025Review
- Biological roles and clinical applications of EpCAM in HCC.Discover oncology · 2025Review
- Cancer stem cells in hepatocellular carcinoma: therapy resistance and emerging treatments.Frontiers in immunology · 2025Review
- Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside.Experimental hematology & oncology · 2022Review
- VEGF-mediated tumour growth and EMT in 2D and 3D cell culture models of hepatocellular carcinoma.Oncology letters · 2022Article
- Degradome-focused RNA interference screens to identify proteases important for breast cancer cell growth.Frontiers in oncology · 2022Article
- Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.Nature reviews. Gastroenterology & hepatology · 2022Review
- RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.Theranostics · 2022Article
- Prognostic Values of BolA Family Member Expression in Hepatocellular Carcinoma.BioMed research international · 2022Article
- SNRPB-mediated RNA splicing drives tumor cell proliferation and stemness in hepatocellular carcinoma.Aging · 2020Article
- Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning.Cancers · 2020Review
- PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2020Article
- Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential.British journal of cancer · 2020Review
- Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma.Stem cell reports · 2020Article
- PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Atsushi Takai *Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Hien Dang *Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Naoki Oishi *Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Subreen KhatibLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Sean P MartinLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-6923-947X
Dana A DominguezLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Ji LuoLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Rachel BagniCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Xiaolin WuCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Katie PowellCancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Qing-Hai YeFudan University, Shanghai, China.
Hu-Liang JiaFudan University, Shanghai, China.
Lun-Xiu QinFudan University, Shanghai, China.
Jinqiu ChenCollaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Gary A MitchellCollaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Xiaoling LuoCollaborative Protein Technology Resource, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Snorri S ThorgeirssonLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. xw3u@nih.gov.ORCID 0000-0001-9735-606X
National Cancer Institute · USLeidos (United States) · USShanghai University of Medicine and Health Sciences · CNThomas Jefferson University · US
Funding
Molecular signatures for liver cancer diagnosis and treatment stratificationZ01BC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 1999 to 2008
$1.8MThe role of cancer stem cells in liver cancer heterogeneity and subtypesZ01BC010876 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$490kThe identification of human hepatocellular carcinoma metastasis genesZ01BC010877 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN · 2008 to 2008
$327kIntramural NIH HHS Z01 BC010313Intramural NIH HHS Z01 BC010876Intramural NIH HHS Z01 BC010877
Abstract
Hepatocellular carcinoma (HCC) is a genetically heterogeneous disease for which a dominant actionable molecular driver has not been identified. Patients with the stem cell-like EpCAM
Indexed as
Genome, HumanRNA InterferenceAnimalsApoptosisCarcinoma, HepatocellularCell ProliferationEpithelial Cell Adhesion MoleculeGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMetalloendopeptidasesMiceMice, NudeMitochondrial Processing PeptidaseNeoplastic Stem CellsProtein SubunitsEPCAM protein, humanEpithelial Cell Adhesion MoleculeMetalloendopeptidasesMitochondrial Processing PeptidaseProtein Subunits
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.